Skip to content

Cryopreserved-thawed Embryo Transfer With or Without Gonadotropin Releasing Hormone Agonist

Cryopreserved-thawed Embryo Transfer in Down or Non-down Regulated Hormonally Controlled Cycles: a Prospective, Randomized Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02736032
Enrollment
310
Registered
2016-04-13
Start date
2016-03-31
Completion date
2018-05-31
Last updated
2018-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Traditionally, the use of GnRH-a suppression was considered essential for adequate endometrial hormonal modulation in cryopreserved-thawed embryo transfer cycles. Several studies, however, have questioned its necessity for controlled endometrial preparation. Using a high dose of estradiol from day 1 of the cycle will suppress the gonadotroph, preventing folliculogenesis and excessive secretion of LH, allowing adequate endometrial preparation without GnRH-a.

Interventions

PROCEDUREEmbryo transfer

The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy

PROCEDURESerum Estradiol and Progesterone levels

Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation

DRUGGnRH agonist

GnRH agonist given on day 21 of the cycle preceding the embryo transfer

DRUGExternal Estradiol

Estradiol started on day1 of the cycle for endometrial prepartaion

DRUGProgesterone

progesterone as luteal phase support start after endometrium is well prepared

Sponsors

Nile Ivf Center, Cairo, Egypt
CollaboratorOTHER
Kamal Shaeer center of infertility
CollaboratorUNKNOWN
Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* 20-35 years * BMI 20-30 * Regular menses. * No PCOS, no endometriosis * No uterine anomalies or lesions * No severe male factor * All grade 1 cleaved stage embryos

Exclusion criteria

* Less than 20 or more than 35 years * BMI less than 20 or more than 30 * Irregular cycles * PCOS or endometriosis * Uterine anomalies or lesions * Severe male factor * Poor quality embryos for transfer * Severe

Design outcomes

Primary

MeasureTime frameDescription
Clinical pregnancy rate5 weeks after embryo transfer]the detection of intrauterine gestational sac with positive pulsations
Live birth rate9 monthsPregnancy ending with a live birth

Secondary

MeasureTime frameDescription
Number of days needed for adequate (> 8mm) endometrial thickness12 to 20 daysNumber of days on external hormones to prepare endometrium
Cycle cancellation: not related to thawing, thin endometrium, high P. OR related to embryos not surviving thawing.12 to 20 daysCycle cancellation: not related to thawing, thin endometrium, high Progesterone. OR related to embryos not surviving thawing.
Chemical pregnancy rate14 days after embryo transferpositive serum Beta HCG 14 days after embryo transfer
Estradiol and Progesterone levels on day of start of progesterone supplementation12 to 20 daysThe serum levels of estradiol and progesterone before embryo transfer
Early miscarriage rate3 monthsPregnancy loss in the first 12 weeks gestation
Ongoing pregnancy rate3 monthsPregnancy ongoing beyond 12 weeks gestation
Implantation rate.5 weeks after embryo transferthe ratio between the number of embryos transferred and the number of sacs
Endometrial thickness on day of start of progesterone supplementation12 to 20 daysThe endometrial thickness on the day of starting progesterone supplementation to transfer the embryos

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026